Sylvie Freeman is Professor of Immunohematology at the University of Birmingham, UK, clinical hematologist and director of the University of Birmingham Clinical Immunophenotyping Service for the diagnosis and monitoring of hematological malignancies. She has co-steered clinical validation and implementation of flow cytometric measurable residual disease testing in AML through multiple UK AML clinical trials since 2005 and an international collaborative network that includes European LeukemiaNet International DAVID, the ASH International Consortium Acute Leukemia and EHA.